Carex relaunches headache band
OAKLAND, Calif. Carex Health Brands on Friday relaunched the Thera-Med headache band, the company announced.
Thera-Med headache band is a cold pack that attaches around the head using a velcro fastener that molds to the body easily.
Micro bead gel innovation keeps the pack soft and flexible for maximum comfort with cold therapy. Featuring advanced Dual-Temp technology, the product has two sides, each made of different materials to provide either gentle cooling or maximum cold.
Public demand from migraine sufferers has prompted Carex to reintroduce the popular Headache Band with an updated design at a suggested retail price of $7.99, the company stated.
Dr. Holmquist Healthcare to distribute bruise relief gel at Walgreens
MANDEVILLE, La. Dr. Holmquist Healthcare on Thursday announced that Walgreens has picked up on its bruise relief gel, a natural formula that helps to eliminate bruising and associated skin discoloration.
“Walgreens distribution and support is a very big deal for Bruise Relief,” stated Barbara Cranner, EVP of Dr. Holmquist Healthcare. “They are the largest retail drug chain in the country selling to our sweet spot audiences of seniors, moms-on-the-go and the beauty conscious.”
Bruise relief gel and bruise relief ultra serum are hydrating formulas that contain vitamins, nutrients and anti-oxidants including glycerin, vitamin E oil and evening primrose oil.
NAD supports Quten Research Institute’s dietary supplement claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus has determined that Quten Research Institute can support certain claims made for its Qunol CoQ10 dietary supplement, though recommended the company modify certain other claims.
NAD, the advertising industry’s self-regulatory forum, examined print and Internet advertising for Qunol CoQ10, following a challenge by the Council for Responsible Nutrition.
The company has said it will appeal a portion of NAD’s decision to the National Advertising Review Board, though Quten Research asserted it had voluntarily discontinued several of the claims at issue — most notably disease-state-type claims that would have run the company afoul of the Federal Trade Commission.
In addition, the Quten represented that it permanently discontinued its “Doctor Recommended CoQ10 Formula” claim and modified its claim “Clinically Proven,” to read, “The hydrosoluble CoQ10 in Qunol softgels has been used in several clinical studies.”
NAD noted that the advertiser had modified its “Clinically Proven” claim to state that “The hydrosoluble CoQ10 in Qunol softgels has been used in several clinical studies,” but found that modified version could be understood by consumers to mean that the product has been proven effective in clinical studies, a claim that is not supported.
NAD found that Qunol provided a reasonable basis for its claims that its Qunol soft gel product is “up to 300% more absorbable…” but recommended that the advertiser clarify the point of comparison – specifically that Qunol is “up to 300% more absorbable” than a standard powder form of CoQ10.
NAD, however, recommended that Qunol discontinue its claim that Liquid Qunol is “Up to 6X better absorption than regular CoQ10.” as well as the claim that “100 mg Qunol Liquid CoQ10 = up to 600 mg regular CoQ10.” since these claims are based solely on the results of laboratory, rather than human, testing.
Qunol, in its advertiser’s statement, stated it respectfully disagrees with NAD’s findings regarding the claim that Qunol liquid CoQ10 provides “up to 6x better absorption,” and will appeal that finding to the National Advertising Review Board.